Vimarsana
Biggest News Aggregation in the World

Page 8 - Timothya Springer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Timothya Springer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Timothya Springer Today - Breaking & Trending Today

Erkki Ruoslahti wins America's top biomedical research award - Vimarsana News

Erkki Ruoslahti wins America's top biomedical research award

La Jolla, CA (PRWEB) September 28, 2022 -- Erkki Ruoslahti, M.D., Ph.D., Distinguished Professor Emeritus at Sanford Burnham Prebys, has been announced as one

Source: prweb.com
World News | Scientists Honoured for COVID-19 Tracker, Prenatal Test - Vimarsana News

World News | Scientists Honoured for COVID-19 Tracker, Prenatal Test

Get latest articles and stories on World at LatestLY. A Johns Hopkins University scientist who created a website to track COVID-19 cases worldwide is the recipient of this year's Lasker award for public service. World News | Scientists Honoured for COVID-19 Tracker, Prenatal Test.

Scientists honored for COVID-19 tracker, prenatal test - Vimarsana News

Scientists honored for COVID-19 tracker, prenatal test

Scientists honored for COVID-19 tracker, prenatal test

Selecta Biosciences (NASDAQ:SELB) Posts Earnings Results, Beats Estimates By $0.09 EPS - Vimarsana News

Selecta Biosciences (NASDAQ:SELB) Posts Earnings Results, Beats Estimates By $0.09 EPS

Selecta Biosciences (NASDAQ:SELB – Get Rating) announced its earnings results on Thursday. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.09, MarketWatch Earnings reports. During the same period in the prior year, the firm earned ($0.14) earnings per share. SELB stock traded down $0.10 during mid-day […]

Seismic raises $101m to advance two drug programmes to clinic - Vimarsana News

Seismic raises $101m to advance two drug programmes to clinic

Seismic Therapeutic has raised $101m in Series A financing led by Lightspeed Venture Partners to advance its first two lead drug programmes to the clinic.